These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 11760780)

  • 1. Oxybutynin and the overactive bladder.
    Andersson KE; Chapple CR
    World J Urol; 2001 Nov; 19(5):319-23. PubMed ID: 11760780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland.
    Waldeck K; Larsson B; Andersson KE
    J Urol; 1997 Mar; 157(3):1093-7. PubMed ID: 9072550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transdermal oxybutynin.
    Baldwin CM; Keating GM
    Drugs; 2009; 69(3):327-37. PubMed ID: 19275276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bryophyllum pinnatum inhibits detrusor contractility in porcine bladder strips--a pharmacological study towards a new treatment option of overactive bladder.
    Schuler V; Suter K; Fürer K; Eberli D; Horst M; Betschart C; Brenneisen R; Hamburger M; Mennet M; Schnelle M; Simões-Wüst AP; von Mandach U
    Phytomedicine; 2012 Jul; 19(10):947-51. PubMed ID: 22824522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladder.
    Staskin DR; Robinson D
    Expert Opin Pharmacother; 2009 Dec; 10(18):3103-11. PubMed ID: 19954278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder-afferent pathways.
    Kim Y; Yoshimura N; Masuda H; de Miguel F; Chancellor MB
    Urology; 2005 Feb; 65(2):238-42. PubMed ID: 15708029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxybutynin topical and transdermal formulations: an update.
    Staskin DR; Salvatore S
    Drugs Today (Barc); 2010 Jun; 46(6):417-25. PubMed ID: 20571610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder.
    Oki T; Kimura R; Saito M; Miyagawa I; Yamada S
    J Urol; 2004 Nov; 172(5 Pt 1):2059-64. PubMed ID: 15540789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urodynamic effects of oxybutynin and tolterodine in conscious and anesthetized rats under different cystometrographic conditions.
    Angelico P; Velasco C; Guarneri L; Sironi G; Leonardi A; Testa R
    BMC Pharmacol; 2005 Oct; 5():14. PubMed ID: 16216132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective action of intravesical oxybutynin on bladder ultrastructure in rabbits with detrusor overactivity.
    Yamamoto H; Kawano PR; Balasteghin KT; Padovani CR; Amaro JL
    Int Urogynecol J Pelvic Floor Dysfunct; 2009 Feb; 20(2):229-34. PubMed ID: 18953475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxybutynin: past, present, and future.
    Jirschele K; Sand PK
    Int Urogynecol J; 2013 Apr; 24(4):595-604. PubMed ID: 22976530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Muscarinic receptor antagonists in the treatment of overactive bladder.
    Chapple CR
    Urology; 2000 May; 55(5A Suppl):33-46; discussion 50. PubMed ID: 10767450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimuscarinic Discontinuation in Patients with Overactive Bladder in Nursing Homes: A Retrospective Study of Medicare Beneficiaries.
    Aparasu RR; Sura S; Earla JR; Shiozawa A; Ng DB; Schermer CR
    Adv Ther; 2020 Aug; 37(8):3584-3605. PubMed ID: 32638205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability.
    Yarker YE; Goa KL; Fitton A
    Drugs Aging; 1995 Mar; 6(3):243-62. PubMed ID: 7620236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.
    Zát'ura F; Vsetica J; Abadías M; Pavlík I; Schraml P; Brod'ák M; Villoria J; Sust M;
    Eur Urol; 2010 Jan; 57(1):145-52. PubMed ID: 19446951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxybutynin for treatment of urge urinary incontinence and overactive bladder: an updated review.
    Abramov Y; Sand PK
    Expert Opin Pharmacother; 2004 Nov; 5(11):2351-9. PubMed ID: 15500382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxybutynin and propiverine suppress adenosine triphosphate-induced bladder overactivity other than through antimuscarinic mechanisms.
    Moon HS; Lee JW; Park SY; Son YW; Kim YT
    Urology; 2010 Aug; 76(2):509.e8-12. PubMed ID: 20546876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological effects of tolterodine on human isolated urinary bladder.
    Yono M; Yoshida M; Wada Y; Kikukawa H; Takahashi W; Inadome A; Seshita H; Ueda S
    Eur J Pharmacol; 1999 Mar; 368(2-3):223-30. PubMed ID: 10193658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of estradiol pretreatment on antimuscarinic action of oxybutynin in rat detrusor muscle.
    Yildiz O; Ozgok Y; Seyrek M; Un I; Kilciler M; Tuncer M
    Urology; 2005 Apr; 65(4):800-3. PubMed ID: 15833550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical experiences with tolterodine.
    Nilvebrant L
    Life Sci; 2001 Apr; 68(22-23):2549-56. PubMed ID: 11392625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.